Hallo! Tracked shipping to Austria with Delivery Duty Paid for just €3.99  

Ship to
Austria
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Neuroprotective vs. Neurostimulating Management Options for Amytrophic Lateral Sclerosis. A Multiple Trial Based Comparison
Type
Physical Book
Author
Publisher
Language
English
Pages
66
Format
Paperback
Dimensions
21x14.8x0.4 cm
Weight
0.10 kg.
ISBN13
9783346217745
Categories

Neuroprotective vs. Neurostimulating Management Options for Amytrophic Lateral Sclerosis. A Multiple Trial Based Comparison

Pranav Jha (Author) · Grin Verlag · Paperback

Neuroprotective vs. Neurostimulating Management Options for Amytrophic Lateral Sclerosis. A Multiple Trial Based Comparison - Jha, Pranav

New Book Imported to Austria
Delivery: 16 Sep - 18 Sep Shipping: 14 to 15 business days.
41,26 €
Import costs and 10% VAT included in the price ✅
41,26 €

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Neuroprotective vs. Neurostimulating Management Options for Amytrophic Lateral Sclerosis. A Multiple Trial Based Comparison"

Doctoral Thesis / Dissertation from the year 2017 in the subject Medicine - Internal Medicine, grade: PG MEDICAL DOCTOR & CEO, University of Buckingham (Ealing Hospital London), course: Doctor Of Clinical Internal Medicine (MD), language: English, abstract: ALS, an incurable fatal syndrome (than being just a misnomer of disease), affecting each organ system and life (quality and quantity), through glutamate induced free radical and electrical injuries to nerves. This giant needs to be further dig into, with deeper investigations for newer management options and betterment of previous treatments, aiming a comparison of various strategies, to invent most sustainable and suitable choice for PALS. Broadly ALS can be classified as sporadic and familial, based on aetiology. There are various subtypes in each of them with regard to the genetic, pathological and nucleic acid mutational conflicts. Like in a case of "Diabetes Mellitus", we don't haphazardly enlist all drugs and precautions, instead first classify them into pharmaco-therapeutic or lifestyle changes, similarly for ALS, I've proposed for a new management classification system for clinical purposes after feeling a need of such, near the end of dissertation. Only approved and unavoidable option in present scenario is glutamic acid release inhibitor "Riluzole" and the basic or standard life care for the disease. Broad spectrum antibiotic "Ceftriaxone" has been found to cross the blood brain barrier and increase GLT-1 channel, leading to fall in glutamate levels of nervous system and hence can be an add-on option to benefit more. RPPX: Dexpramipexole; recently developed drug especially for SOD-1 and TDP-43 mutation ALS, showed mitochondrial protection and reciprocated it as improved ALSFRS. Though the medication can be a future option, but for now trials have failed to reflect major benefit on a 12-month follow up. MCI186: Edaravone, by virtue of being antioxidant in character (supposedly); has gained F

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews